Europe — EMA
Noraminophenazoni Fono Vii. Naturland (Metamizole Sodium Monohydrate)
GNH USA supplies Noraminophenazoni Naturland (Metamizole Sodium), a pyrazolone analgesic and antipyretic for pain, fever and colic.
Request sourcing
What is Metamizole Sodium Monohydrate?
Metamizole sodium monohydrate, the active ingredient in Noraminophenazoni Fono Vii. Naturland, is a pyrazolone presented as a rectal formulation for rectal use. It provides analgesic and antipyretic effects for the treatment of pain, fever and colic in adults.
GNH USA supplies Noraminophenazoni Fono Vii. Naturland as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Metamizole Sodium Monohydrate used for?
Metamizole sodium monohydrate is used to manage pain and fever through inhibition of prostaglandin-mediated pathways.
- Pain: reduces moderate to severe acute pain. - Fever: lowers elevated body temperature. - Colic: alleviates abdominal cramping associated with colic.
What are the side effects of Metamizole Sodium Monohydrate?
Metamizole sodium monohydrate may cause a range of adverse reactions, from mild to severe.
Common Side Effects: - Nausea - Dizziness - Rash - Headache
Serious or Rare Side Effects: - Agranulocytosis - Severe skin reactions such as Stevens‑Johnson syndrome - Anaphylactic reaction
What precautions apply to Metamizole Sodium Monohydrate?
When using Metamizole sodium monohydrate, consider the following safety measures.
- Blood count monitoring: check for neutropenia before and during therapy. - Renal function assessment: adjust use in patients with renal impairment. - Hypersensitivity evaluation: avoid in individuals with known allergy to pyrazolones. - History of agranulocytosis: contraindicated in patients with prior episodes. - Store at room temperature: keep in original packaging, protect from moisture and heat.
What does Metamizole Sodium Monohydrate interact with?
Metamizole sodium monohydrate can interact with several drug classes; awareness helps prevent adverse outcomes.
Major Interactions (Avoid): - Concurrent myelosuppressive agents: increased risk of severe blood dyscrasias. - Other NSAIDs or pyrazolones: additive gastrointestinal and renal toxicity. - Anticoagulants: heightened bleeding tendency.
Moderate Interactions (Monitor Closely): - ACE inhibitors: potential for enhanced hypotensive effect. - Diuretics: may exacerbate electrolyte disturbances. - Alcohol: increased risk of gastrointestinal irritation.



